Soligenix (SNGX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Aug, 2026Executive summary
Annual meeting scheduled for September 17, 2026, with virtual participation available.
Shareholders are invited to vote on key proposals, including board elections, amendments to the certificate of incorporation, and executive compensation.
Voting matters and shareholder proposals
Election of five directors to serve until the next annual meeting or until successors are elected.
Proposal to approve a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the board's discretion, effective for up to one year.
Proposal to increase authorized common stock from 75,000,000 to 125,000,000 shares.
Advisory vote on executive compensation and on the frequency of such advisory votes.
Ratification of Cherry Bekaert LLP as independent auditor for the year ending December 31, 2026.
Approval to adjourn the meeting if necessary to solicit more proxies.
Board of directors and corporate governance
Nominees for director positions include Christopher J. Schaber, Gregg A. Lapointe, Diane L. Parks, Robert J. Rubin, and Jerome B. Zeldis.
Latest events from Soligenix
- Net loss narrowed on lower R&D costs, but going concern and Nasdaq delisting risks persist.SNGX
Q2 2026 - Proxy seeks approval for reverse split, share increase, and highlights governance and ESG focus.SNGX
Proxy filing - Reverse split and share increase proposed to maintain Nasdaq listing and enable future growth.SNGX
Proxy filing - Proxy seeks approval for reverse split, share increase, director elections, and executive pay.SNGX
Proxy filing - Net loss narrowed, FLASH2 trial halted, focus shifts to pipeline amid funding risks.SNGX
Q1 2026 - Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation - Net loss rose to $11.1M in 2025, with liquidity concerns and new capital needed for continued operations.SNGX
Q4 2025 - Late-stage rare disease therapies and vaccines show strong clinical and commercial promise.SNGX
Corporate presentation - Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation